INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
Hedley Rees' Expert Statement on SARS-CoV-2 injections, Written December 17, 2021: PART 2

Hedley Rees' Expert Statement on SARS-CoV-2 injections, Written December 17, 2021: PART 2

Licensing drugs

Hedley Rees's avatar
Hedley Rees
Dec 06, 2024
∙ Paid
12

Share this post

INSIDE PHARMA
INSIDE PHARMA
Hedley Rees' Expert Statement on SARS-CoV-2 injections, Written December 17, 2021: PART 2
1
4
Share

Share

For those who missed PART 1, here it is:

Hedley Rees' Expert Statement on SARS-CoV-2 injections, Written December 17, 2021: PART 1

Hedley Rees' Expert Statement on SARS-CoV-2 injections, Written December 17, 2021: PART 1

Hedley Rees
·
December 2, 2024
Read full story

THE PROCESS OF LICENSING

The process consists of licensing companies to undertake clinical studies in humans, and, if successful, licensing the company to sell the approved product(s) under strict terms of the license.

The licenses are awarded by the competent authority responsible for medicines and healthcare products in each country or region. In the United States, it is the FDA (we will use the US as an example, but all are similar or the same).

The license to run a clinical trial is known as a Clinical Trial Application.

The application must include an investigational medical product dossier (IMPD), with details of the supply chain that will be employed to manufacture clinical trial supplies.

1. Preclinical development and Preclinical development supply chain

Patients receive injections that are produced by the supply chain, so it is crucially important that safety testing is carried out on the batches produced.

The diagram below shows the precli…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Hedley Rees
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share